On December 19, 2025, Boston Scientific issued a field safety notice recommending removal of certain AXIOS Stents and electrocautery-enhanced delivery systems due to deployment failures. As of December 23, the company had logged 167 serious injuries and three fatalities related to devices that could not fully expand at deployment. The U.S. Food and Drug Administration has classified this as a potentially high-risk device issue and is actively reviewing the case. Notably, this follows Medtronic’s own December recall of Left Heart Vent Catheters citing malleability defects. Investors should monitor potential ripple effects in FDA device enforcement and reputational impacts across the structural heart device sector.

Medtronic is on track to raise its quarterly dividend for the 48th year in a row, underscoring its commitment to returning capital to shareholders. The company’s Pulsed Field Ablation (PFA) business, now deployed in over 350 U.S. hospitals since FDA approval in 2022, and the Symplicity renal denervation system for hypertension, which posted 25% year-over-year revenue growth in Q2 FY26, are the primary drivers. Medtronic maintains an ‘A’ credit rating from S&P with a stable outlook, reflecting strong free cash flow generation—exceeding $3.5 billion in the trailing twelve months—and disciplined capital allocation. This dividend track record and robust balance sheet support its status as a Dividend Aristocrat in the medical technology space.